Clinical Trials Logo

Intracranial Neoplasm clinical trials

View clinical trials related to Intracranial Neoplasm.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05145049 Completed - Brain Tumor Clinical Trials

The Relationship of Anesthesia Method With Serum Lactate Level in Craniotomies

Start date: November 1, 2021
Phase:
Study type: Observational [Patient Registry]

The investigators aimed to research the incidence of hyperlactatemia in craniotomy cases, the relationship of lactate elevation with tumor type and other factors that may be related, and whether the general anesthesia method applied (inhalation anesthesia or total ıntravenous anesthesia) affects lactate level.

NCT ID: NCT04454268 Completed - Clinical trials for Intracranial Neoplasm

Intracranial Hydatid Cyst

Start date: January 1, 2010
Phase: N/A
Study type: Interventional

Central nervous system (CNS) hydatid cysts is a rare presentation of hydatid cyst, although may be the cause of intracranial space-occupying lesions in 4% in endemic countries. It affects mostly children. The diagnosis of CNS hydatid is still problematic in spite of the advancements in imaging techniques (CT or MRI). Extirpation of the intact cyst is the treatment of choice, resulting in most cases to a complete recovery.

NCT ID: NCT04302857 Completed - Clinical trials for Intracranial Neoplasm

Tractography Pilot Study Leipzig

Start date: January 1, 2020
Phase:
Study type: Observational

In this pilot study participants will undergo routine magnetic resonance imaging and routine neurosurgical care. By prospectively collecting data from both MRI and patient records we want to investigate biomarkers derived from tractography and diffusion tensor imaging to predict rehabilitation potential.

NCT ID: NCT04044937 Completed - Clinical trials for Recurrent Glioblastoma

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

UC-GlioFET
Start date: October 29, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.

NCT ID: NCT03710278 Completed - Clinical trials for Subarachnoid Hemorrhage

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

LPat
Start date: December 21, 2017
Phase:
Study type: Observational

The purpose of this study is to proof and investigate the effectiveness and safety of the invented device named "Human Lumbar Puncture Assist Device (LPat)" as an assist tool to be utilized to improve the success rate of performing lumbar puncture (LP), avoid side effects from multiple punctures, avoid excess radiation if the LP need to be done under fluoroscopy, and need to obtain none traumatic tap for better CSF analysis.

NCT ID: NCT03539731 Completed - Glioblastoma Clinical Trials

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Start date: April 23, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors or recurrent glioblastoma and healthy volunteers. PKM2 regulates brain tumor metabolism, a key factor in glioblastoma growth. [18F]DASA-23 is a radioactive substance with the ability to monitor PKM2 activity. A PET scan is a procedure in which a small amount of a radioactive substance, such as [18F]DASA-23, is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the substance is used. Tumor cells usually pick up more of these radioactive substances, allowing them to be found. Giving [18F]DASA-23 with a PET scan may help doctors evaluate PKM2 expression in healthy volunteers and in participants with intracranial tumors or recurrent glioblastoma.

NCT ID: NCT03076255 Completed - Clinical trials for Head and Neck Cancer

Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy

Start date: February 24, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well head and neck maskless immobilization device works in immobilizing patients with head and neck cancers or intracranial tumors undergoing radiation therapy. Maskless immobilization device may help to prevent movement of head during radiation therapy and immobilize patients with the same accuracy and reliability as the standard thermoplastic mask routinely used for patients receiving radiation therapy.